Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Up 0.1%

GILD stock traded up $0.09 during midday trading on Monday, reaching $129.67. The company’s stock had a trading volume of 5,181,495 shares, compared to its average volume of 6,755,550. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a fifty day simple moving average of $137.76 and a two-hundred day simple moving average of $133.31. Gilead Sciences, Inc. has a 1 year low of $102.84 and a 1 year high of $157.29. The firm has a market capitalization of $160.99 billion, a price-to-earnings ratio of 17.67 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the firm posted $1.81 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently made changes to their positions in GILD. Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences during the fourth quarter valued at about $517,808,000. Massachusetts Financial Services Co. MA boosted its position in Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Bank of America Corp DE boosted its position in Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after purchasing an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Royal Bank Of Canada reduced their target price on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research note on Friday, May 8th. Scotiabank increased their target price on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Citigroup increased their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Wolfe Research increased their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $157.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.